INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) was defined in the 2008 World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissue as a malignant proliferation of blastic plasmacytoid dendritic cells. 1 The skin lesions appear as bruiselike erythematous nodules or tumors and are usually found already at presentation. BPDCN is highly malignant, with a mean survival time of 15.2 months. 2 Data are limited concerning patients with localized skin-limited BPDCN (LS-BPDCN).
We report our experience with 2 patients with LS-BPDCN, both of whom achieved potential cure with hyper-CVAD chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone) followed by consolidative localized radiotherapy (LRT), without hematopoietic stem cell transplantation (HSCT).
CASE DESCRIPTIONS
The first patient was a 38-year-old white man and the second was a 23-year-old Asian woman. Sites of occurrence were the forearm (patient 1 ; Fig 1, A) and forehead (patient 2 ; Fig 1, B) . In both cases, the lesion started as a solitary papule/plaque. The forehead lesion was initially diagnosed clinically as a pimple. The lesions enlarged within weeks to months to form tumors (largest diameter, 6-8 cm) with a dusky, purplish/violet, or bruiselike appearance; in one case, the lesion was ulcerated (Fig 1, B) . The patients had no systemic complaints. No lymphadenopathy or hepatosplenomegaly was noted on examination.
Complete blood count, comprehensive metabolic profile, and serum lactate dehydrogenase level were within normal range. Findings on bone marrow biopsy, whole-body positron emission tomographyecomputed tomography were unremarkable.
Histopathologic findings were remarkable for a dense dermis-based monomorphous infiltrate Abbreviations used:
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Both patients were treated with combination chemotherapy, completing 4 cycles of hyper-CVAD, alternating with methotrexate and cytarabine (A1B). One month after chemotherapy, both underwent consolidative LRT (36 Gy). Clinical remission was achieved ( Fig 2, A and B) and has been sustained so far for 6 years (patient 1) and 9 years (patient 2), without HSCT.
DISCUSSION
Only 19 patients with LS-BPDCN have been reported in the literature since the latest classification of BPDCN in 2008, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] (their data are summarized in Table I ). Median age of the reported patients at presentation was 46 years (range, 5-83), which is younger than the median age documented for all patients with BPDCN (67.8 years). 2 None of the reports mentioned time to diagnosis from initial evaluation by a clinician. In our patient 2, the diagnosis was delayed by 5 months, suggesting that LS-BPDCN is not always recognized by clinicians at presentation. A delay in diagnosis poses a risk of disease progression.
In 15 of the total 21 patients with LS-BPDCN (current work and the literature, 71%), the lesion was located on the upper part of the body. It was clinically described as a violaceous, bruiselike erythematous nodule/tumor.
There is no established standard frontline treatment for BPDCN. Some evidence supports the use of an acute lymphoblastic leukemia (ALL)-like protocol (eg, hyper-CVAD) over acute myelogenous leukemiaelike protocols. 13 Current active clinical trials are exploring novel treatments including targeted therapies (SL-401, XmAb14045) and genetically modified T-cell immunotherapy. Promising results have been reported for SL-401, a diphtheria toxin conjugated to interleukin-3, directed to the interleukin-3 receptor (CD123), a target overexpressed on BPDCN. According to the preliminary results of a phase 2 registration clinical trial in patients with BPDCN, SL-401 showed robust single-agent activity, including 100% overall response rate in first-line patients and 87% in all lines, with multiple complete responses; response duration data are being processed and are so far encouraging (presented at the 2016 American Society of Clinical Oncology and American Society of Hematology Annual Meetings, NCT02113982). A study of the benefit of HSCT showed that the difference in mean overall survival time between those who underwent transplantation (9 allogeneic [allo], 1 autologous) and those who did not was highly significant (31.3 vs 12.8 months; P = .0018). 4 Less information is available on the optimal therapeutic approach to LS-BPDCN specifically. Table I lists the treatments used in the 19 patients previously reported in the literature. Conclusions are difficult to reach because the chemotherapy protocols were not uniform, and not all patients received additional LRT. Furthermore, there are almost no data on the role of HSCT in LS-BPDCN. If we extrapolate from the limited experience with isolated myeloid sarcoma, we may conclude that allo-HSCT may not be the best first-line therapy. 14 Of the total 21 patients with LS-BPDCN (current report and the literature), 4 underwent HSCT (3 allo-HSCT, 1 auto-HSCT), of whom, 2 died (1 of the disease; in 1 the cause of death was not reported). Thus, the benefit of HSCT in LS-BPDCN is unclear. Both patients presented here showed disease regression without HSCT.
Overall, prognostic data are available for 18 of 19 patients with LS-BPDCN reported in the literature. Median duration of follow-up was 16 months (range, 1-66), and 10 patients died of the disease. In contrast, both our patients achieved potential cure during follow-up of 6 and 9 years. Both were treated with ALL-like (hyper-CVAD, A1B) chemotherapy protocol and consolidative LRT. To our knowledge, there are no reports specifically addressing the use of this protocol as the initial treatment for primary LS-BPDCN. Beyond treatment type, it is possible that the long-term response of our patients may be attributable partly to yet undefined but different biological activity/characteristics of LS-BPDCN tumors.
To prevent a delay in diagnosis, clinicians should be aware of the appearance of primary LS-BPDCN at presentation, mainly as a violaceus, bruiselike, infiltrated plaque or tumor, usually on the upper part of the body. According to our experience, in age-appropriate cases of LS-BPDCN, initial treatment with aggressive combination chemotherapy, with some evidence supporting ALL-like regimens, followed by consolidation with LRT, even without HSCT, may achieve long-lasting remissions if not cure. 
